Compare Alcon AG (ALC) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Enveric Biosciences Inc — how do they compare? Alcon AG trades at $72.96 (market cap $36.44B), while Enveric Biosciences Inc trades at $1.45 (market cap $6.20M). The key difference: Alcon AG is far larger — about 5877.4× Enveric Biosciences Inc's market cap, and Alcon AG pays a 0.48% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ALC | ENVB | |
|---|---|---|
Market Cap | $36.44B | $6.20M |
Sector | Health | Health |
52-Week High | $90.12 | $17.40 |
52-Week Low | $62.02 | $1.27 |
Enterprise Value | $40.28B | $1.30M |
Dividend Yield | 0.48% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
